Pharmaceuticals, Biotechnology & Life Sciences

Explore how aTyr Pharma’s insider option activity signals leadership confidence amid dilution risk, and what milestones investors should watch to gauge future upside.

Rule 10b5‑1 insider sale at Xeris Biopharma shows routine liquidity management; strong pipeline, safety data, and revenue guidance keep long‑term growth intact.

CEO’s insider option buy signals confidence in Anavex’s Alzheimer drug blarcamesine and its market‑access strategy, hinting at future upside for investors.

Oncolytics Biotech insider buying shows long‑term confidence in its reovirus platform, regulatory shift to Nevada, and patent expansion—signals to watch for future upside.

Insider buys reveal TG Therapeutics’ confidence: CFO’s long‑term stake and CEO’s open‑market purchase hint at undervaluation and future growth amid market volatility.

Insider sell‑to‑cover at Avidity Biosciences shows execs stay long‑term on the sidelines while the company pursues antibody‑oligonucleotide breakthroughs—read why this matters for investors.

BioVie’s insider option buying signals executive confidence in its Parkinson’s and liver‑cirrhosis pipeline, hinting at potential upside if FDA milestones are met.

Neumora Therapeutics’ insider buying surge shows board confidence in a promising Parkinson’s pipeline, strong Phase II safety, and a clear path to FDA approval, making it a hot watch for investors in neuro‑therapeutics.

Merck’s final insider deal completes its takeover of Cidara Therapeutics—closing a cashless, $221.50‑per‑share merger that adds a promising anti‑infective pipeline and boosts investor confidence.

Ionis insider buying signals confidence in its RNA platform and highlights the shift to tech‑enabled, value‑based healthcare delivery and reimbursement models.